TriangleHEALTH PROFESSIONAL · SOURCE READING
Sunitinib
Source: Childhood Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 12, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Childhood Thymoma / Treatment of Childhood Thymoma
In an open-label phase II study of sunitinib in adult patients with refractory thymomas, partial responses were observed in 6% of patients, and stable disease was achieved in 75% of patients.[14]
Source links and citations
For more information about the treatment of thymomas, see Thymoma and Thymic Carcinoma Treatment.
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice